EVHHealthcare · Health Information ServicesEVH Stock Forecast: Evolent Health, Inc. Price Predictions for 2026-2027
The 14 Wall Street analysts covering Evolent Health, Inc. hold a median 12-month price target of $6 — +91.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 1 Aug 2026 — in the upper half.
EVH stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Evolent Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (8): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Evolent Health, Inc. — and when they’d sell — is the membership.
EVH stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on EVH, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +91.1% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | TD Cowen | Maintains | Buy | $8.00 → $5.00 |
| 23 July 2026 | Citigroup | Downgrade | Neutral | $5.50 → $6.75 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $6.00 → $7.00 |
| 30 June 2026 | Truist Securities | Downgrade | Hold | — |
| 30 June 2026 | Truist Securities | Downgrade | Hold | $7.00 |
| 12 June 2026 | Truist Securities | Maintains | Buy | — |
| 15 May 2026 | Citigroup | Maintains | Buy | — |
| 12 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 7 May 2026 | Needham | Maintains | Buy | — |
| 2 Mar 2026 | Oppenheimer | Maintains | Outperform | — |
| 26 Feb 2026 | Citigroup | Maintains | Buy | — |
| 26 Feb 2026 | Truist Securities | Maintains | Buy | — |
| 26 Feb 2026 | UBS | Maintains | Buy | — |
| 25 Feb 2026 | BTIG | Maintains | Buy | — |
| 25 Feb 2026 | Keybanc | Downgrade | Sector Weight | — |
| 25 Feb 2026 | Needham | Maintains | Buy | — |
| 25 Feb 2026 | RBC Capital | Maintains | Sector Perform | — |
| 2 Feb 2026 | BTIG | Maintains | Buy | — |
| 9 Jan 2026 | Citigroup | Maintains | Buy | — |
| 6 Jan 2026 | Citizens | Maintains | Market Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EVH analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Evolent Health, Inc. (EVH) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.6×
- Price / sales
- 0.2×
- Price / book
- 0.9×
- EV / EBITDA
- 16.0×
Cheaper than 80% of US stocks
Cheaper than 93% of US stocks
Cheaper than 75% of US stocks
Cheaper than 22% of US stocks
- Revenue growth (YoY)
- 2.6%
- Earnings growth (YoY)
- —
- Gross margin
- 16.9%
- Operating margin
- −2.0%
- Net margin
- −26.3%
Higher than 35% of US stocks
Higher than 18% of US stocks
Higher than 33% of US stocks
Higher than 14% of US stocks
- Return on equity
- −65.1%
- Return on assets
- −0.4%
- Dividend yield
- —
Higher than 18% of US stocks
Higher than 42% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
EVH vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EVH appears on the weeks it earns a place.
Frequently asked questions about EVH stock
What is the EVH stock price forecast for 2026-2027?
The 14 Wall Street analysts covering Evolent Health, Inc. have a median 12-month price target of $6, with estimates ranging from $3 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is EVH stock a buy right now?
Of the 14 analysts covering Evolent Health, Inc., 10 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evolent Health, Inc. 58 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank EVH?
As at 1 Aug 2026, Evolent Health, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
Will EVH stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts implies +91.1% from the last close, and Ticker Nerd's factor model ranks Evolent Health, Inc. 58 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the EVH stock forecast for 2030?
No analyst covering Evolent Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EVH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $8 over the next 12 months.
How has EVH stock performed over the past year?
Evolent Health, Inc. returned -68.5% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Evolent Health, Inc. do?
Evolent Health Inc. is a healthcare solutions company that partners with healthcare providers to enhance patient care through innovative technology and services.
About Evolent Health, Inc.
Evolent Health Inc. is a healthcare solutions company that partners with healthcare providers to enhance patient care through innovative technology and services. Primarily focused on driving value-based care, Evolent Health provides a comprehensive platform integrating clinical and administrative tools designed to improve patient outcomes while reducing the costs associated with healthcare delivery. The company serves a wide array of clients, including hospitals, health systems, and physician organizations, helping them navigate the transition from fee-for-service to value-based care models. Evolent's services encompass a range of areas such as population health management, analytics, and care coordination. Founded in 2011 and headquartered in Arlington, Virginia, Evolent Health holds a significant position within the healthcare sector by enabling institutions to implement personalized and efficient care strategies. Its role in the financial market is underscored by the growing emphasis on cost-effective health management, making it a key player in addressing evolving healthcare trends and policies.
CEO Mr. Seth Barrie Blackley · 4,200 employees · United States · https://www.evolent.com